Calcium Channel alpha-1 Polypeptide as a Drug Target and Biomarker for the Treatment of Hypokalemia and Paralysis

Target Name: CACNA1S

NCBI ID: G779

CACNA1S

Calcium Channel alpha-1 Polypeptide as a Drug Target and Biomarker for the Treatment of Hypokalemia and Paralysis

Hypokalemia, or low potassium levels, is a common disorder that affects millions of people worldwide. It can cause muscle weakness, cardiac arrhythmias, and other serious complications if left untreated. One of the main forms of hypokalemia is periodic paralysis, a genetic disorder that causes muscle weakness and wasting in the absence of adequate calcium. The calcium channel alpha-1 polypeptide (CACNA1S) is a protein that plays a crucial role in muscle function, and its dysfunction has been implicated in the development and progression of periodic paralysis. As a result, CACNA1S has emerged as a promising drug target and biomarker for the treatment of hypokalemia and periodic paralysis.

CACNA1S: Structure and Function

CACNA1S is a 22-kDa calcium channel that is expressed in skeletal muscles, heart, and other tissues. It consists of a 154 amino acid residue that contains a N-terminus, a catalytic C-terminus, and a C-terminal hypervariable region (HVR). The HVR is involved in the interaction between CACNA1S and its ligands, which include calcium ions and other molecules.

CACNA1S functions as a calcium channel, allowing calcium ions to enter the muscle cells and regulate muscle contractions. It is a critical channel for the regulation of muscle strength and function, and its dysfunction has been implicated in the development and progression of periodic paralysis.

CACNA1S is a natural compound that has been identified in the tissues of individuals with periodic paralysis. It has been shown to be expressed in muscle fibers, and its levels are decreased in individuals with periodic paralysis. Additionally, studies have shown that individuals with periodic paralysis have reduced levels of CACNA1S in their muscles, which may contribute to the worsening of muscle weakness and dysfunction.

Drug Targeting and Biomarker

The CACNA1S protein is a potential drug target for the treatment of hypokalemia and periodic paralysis due to its involvement in the regulation of muscle function. Calcium channels are involved in the regulation of muscle strength and function, and their dysfunction has been implicated in the development and progression of periodic paralysis. By targeting the CACNA1S protein, drugs can potentially improve muscle strength and function in individuals with periodic paralysis.

In addition to its potential as a drug target, CACNA1S has also been identified as a biomarker for the diagnosis and monitoring of periodic paralysis. The reduced levels of CACNA1S in muscle fibers of individuals with periodic paralysis suggest that it may be a useful biomarker for the diagnosis of this disorder. Additionally, the levels of CACNA1S in muscle fibers have been shown to be decreased in individuals with periodic paralysis, which may indicate that it is a useful biomarker for monitoring the effectiveness of potential treatments.

Targeting CACNA1S

There are several strategies that can be used to target the CACNA1S protein. One approach is to use small molecule inhibitors to prevent the interaction of CACNA1S with its ligands, such as calcium ions. Another approach is to use antibodies to block the function of CACNA1S and prevent it from regulating muscle function.

Antibodies against CACNA1S have been shown to be effective in blocking its function and improving muscle strength in individuals with periodic paralysis. Additionally, antibodies against CACNA1S have been shown to be effective in preventing the development of muscle weakness in individuals with periodic paralysis.

Another approach to targeting CACNA1S is to use drugs that modulate its expression or function. For example, drugs that

Protein Name: Calcium Voltage-gated Channel Subunit Alpha1 S

Functions: Pore-forming, alpha-1S subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle. Calcium channels containing the alpha-1S subunit play an important role in excitation-contraction coupling in skeletal muscle via their interaction with RYR1, which triggers Ca(2+) release from the sarcplasmic reticulum and ultimately results in muscle contraction. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group

The "CACNA1S Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNA1S comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets